Bumper Offer - Urjas oil Just @ Rs. 1
Ramistar 1.25 Tablet (15), a prescription drug, is manufactured in various forms such as Tablet. It is primarily used for the treatment of High BP. Ramistar 1.25 Tablet (15) also has some secondary and off-label uses. These are listed below.
The optimal dosage of Ramistar 1.25 Tablet (15) is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
The most common side effects of Ramistar 1.25 Tablet (15) are Confusion. While these are the most often observed Ramistar 1.25 Tablet (15) side effects, there are can be others also. These have been listed below. Usually, these side effects of Ramistar 1.25 Tablet (15) go away soon, and do not persist beyond the duration of the treatment. If, however, they worsen or do not go away, please speak with your physician.
Ramistar 1.25 Tablet (15)'s effect during pregnancy is Severe and Mild while nursing. In addition, Ramistar 1.25 Tablet (15)'s effects on the liver, heart and kidney are discussed below in the Ramistar 1.25 Tablet (15) related warnings section.
Ramistar 1.25 Tablet (15) is contraindicated in people with pre-existing medical conditions like Angioedema, Heart Failure, Low Blood Pressure (Hypotension) as it can result in adverse effects. Other contraindications of Ramistar 1.25 Tablet (15) have been discussed in the sections ahead.
Drug interactions for Ramistar 1.25 Tablet (15) have been reported in the medical literature. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Ramistar 1.25 Tablet (15) is considered not safe while driving, and is not addictive.
Ramistar 1.25 Tablet (15) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Based on research, the following side effects have been observed when Ramistar 1.25 Tablet (15) is used -
Mild
Common
Is the use of Ramistar 1.25 Tablet (15) safe for pregnant women?
Ramistar should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Ramistar 1.25 Tablet (15) safe during breastfeeding?
Ramistar may have very limited harmful effects for breastfeeding women.
What is the effect of Ramistar 1.25 Tablet (15) on the Kidneys?
Ramistar rarely affects the kidneys.
What is the effect of Ramistar 1.25 Tablet (15) on the Liver?
Ramistar has very mild side effects on the liver.
What is the effect of Ramistar 1.25 Tablet (15) on the Heart?
Ramistar may have mild side effects on the heart. Most people will never see any effect on the heart.
Ramistar 1.25 Tablet (15) should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Ramistar 1.25 Tablet (15) unless your doctor advises you to do so -
Is this Ramistar 1.25 Tablet (15) habit forming or addictive?
Ramistar 1.25 Tablet (15) does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
No, you should do not do anything that requires concentration and attention as the Ramistar 1.25 Tablet (15) can make you feel drowsy.
Is it safe?
Ramistar 1.25 Tablet (15) should be used only after doctor's advice.
Is it able to treat mental disorders?
No, the use of Ramistar 1.25 Tablet (15) in mental disorders is not effective.
Interaction between Food and Ramistar 1.25 Tablet (15)
Taking Ramistar 1.25 Tablet (15) with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Ramistar 1.25 Tablet (15)
It is difficult to say anything about the effect of Ramistar 1.25 Tablet (15) and alcohol. No research has been done on this yet.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503